Tecentriq, an immuno-cancer drug from Roche Korea, will be expanded from next month due to a combination treatment with Avastin.

The new insurance drug price is 2,271,109 won per 20mL for Tecentriq, 218,782 won per 100mg for Avastin, and 712,098 won for Avastin 400mg.

The MOHW announced that the "Amendment to the Pharmaceutical Benefit List," which aims to expand the standard for immuno-cancer drugs, was passed after presenting it as a resolution by the 10th Health Insurance Policy Review Committee today (29th).

These drugs were listed in January 2018 as the current NSCLC secondary therapy and urinary tract epithelial cancer treatment, and have also been receiving benefits